-+ 0.00%
-+ 0.00%
-+ 0.00%

Eton Pharmaceuticals' ET-700 shows fewer treatment-related adverse events than Galzin in pilot study

PUBT·11/05/2026 21:09:54
Listen to the news
Eton Pharmaceuticals' ET-700 shows fewer treatment-related adverse events than Galzin in pilot study
  • Eton Pharmaceuticals announced preliminary pilot study results for ET-700, its investigational extended-release zinc acetate treatment for Wilson disease.
  • ET-700 showed better gastrointestinal tolerability than GALZIN but weaker inhibition of copper absorption.
  • No serious adverse events occurred during the four-week study involving 36 healthy participants.
  • Additional study arms planned for 2027 will evaluate faster-release formulations to improve copper absorption inhibition while preserving tolerability.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051601PRIMZONEFULLFEED9871415) on November 05, 2026, and is solely responsible for the information contained therein.